Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy IVERIC bio stock | $7.5

Own IVERIC bio stock in just a few minutes.

Fact checked

IVERIC bio, Inc is a biotechnology business based in the US. IVERIC bio shares (ISEE) are listed on the NASDAQ and all prices are listed in US Dollars. IVERIC bio employs 55 staff and has a market cap (total outstanding shares value) of USD$622.5 million.

How to buy shares in IVERIC bio

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for IVERIC bio. Find the stock by name or ticker symbol: ISEE. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until IVERIC bio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$7.5, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of IVERIC bio, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of IVERIC bio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

IVERIC bio share price

Use our graph to track the performance of ISEE stocks over time.

IVERIC bio shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$7.5
52-week rangeUSD$2.64 - USD$8.97
50-day moving average USD$6.6185
200-day moving average USD$5.5082
Wall St. target priceUSD$13
PE ratio 3.4971
Dividend yield N/A (0%)
Earnings per share (TTM) USD$1.527

Buy IVERIC bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy IVERIC bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

IVERIC bio price performance over time

Historical closes compared with the close of $7.5 from 2020-12-18

1 week (2021-01-09) N/A
1 month (2020-12-18) 7.5
3 months (2020-10-16) 17.55%
6 months (2020-07-17) 64.84%
1 year (2020-01-17) 10.62%
2 years (2019-01-18) 439.57%
3 years (2018-01-18) 155.10%
5 years (2016-01-16) N/A

Is IVERIC bio under- or over-valued?

Valuing IVERIC bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IVERIC bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

IVERIC bio's P/E ratio

IVERIC bio's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, IVERIC bio shares trade at around 3x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

IVERIC bio financials

Gross profit TTM USD$-39,644,000
Return on assets TTM -30.4%
Return on equity TTM -50.38%
Profit margin 0%
Book value $2.396
Market capitalisation USD$622.5 million

TTM: trailing 12 months

Shorting IVERIC bio shares

There are currently 3.7 million IVERIC bio shares held short by investors – that's known as IVERIC bio's "short interest". This figure is 2.4% up from 3.7 million last month.

There are a few different ways that this level of interest in shorting IVERIC bio shares can be evaluated.

IVERIC bio's "short interest ratio" (SIR)

IVERIC bio's "short interest ratio" (SIR) is the quantity of IVERIC bio shares currently shorted divided by the average quantity of IVERIC bio shares traded daily (recently around 689387.10865562). IVERIC bio's SIR currently stands at 5.43. In other words for every 100,000 IVERIC bio shares traded daily on the market, roughly 5430 shares are currently held short.

However IVERIC bio's short interest can also be evaluated against the total number of IVERIC bio shares, or, against the total number of tradable IVERIC bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IVERIC bio's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 IVERIC bio shares in existence, roughly 40 shares are currently held short) or 0.0475% of the tradable shares (for every 100,000 tradable IVERIC bio shares, roughly 48 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against IVERIC bio.

Find out more about how you can short IVERIC bio stock.

IVERIC bio share dividends

We're not expecting IVERIC bio to pay a dividend over the next 12 months.

IVERIC bio share price volatility

Over the last 12 months, IVERIC bio's shares have ranged in value from as little as $2.64 up to $8.97. A popular way to gauge a stock's volatility is its "beta".

ISEE.US volatility(beta: 1.63)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IVERIC bio's is 1.632. This would suggest that IVERIC bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

IVERIC bio overview

IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration. It is also developing High temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company has a license agreement with the University of Florida Research Foundation and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and Best disease and other BEST1-related inherited retinal diseases. It also has a research agreement with the University of Massachusetts Medical School to develop gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and autosomal recessive Stargardt disease; and IRDs associated with mutations in the USH2A gene. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site